Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer-Reference-Cited by-同舟云学术

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

Published:2011-09-13 Issue:8 Volume:105 Page:1144-1150
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Lee C K,Simes R J,Brown C,Lord S,Wagner U,Plante M,Vergote I,Pisano C,Parma G,Burges A,Bourgeois H,Högberg T,Bentley J,Angleitner-Boubenizek L,Ferrero A,Richter B,Hirte H,Gebski V,Pfisterer J,Pujade-Lauraine E,Friedlander M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2011364.pdf

Reference33 articles.

1. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, Kaye SB, Shepherd JH, Van Trappen PO (2008) Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 138: 71–75

2. Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59: 650–653

3. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell’Anna T, Torri V, Colombo N (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20: 1232–1237

4. Cho H, Hur H, Kim S, Kim S, Kim J, Kim Y, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58: 15–23

5. Cox D (1972) Regression models and life-tables. J R Stat Soc B 34: 187–220

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological Nomogram for Predicting Platinum-Resistant/Refractory Epithelial Ovarian Cancer;Indian Journal of Gynecologic Oncology;2024-04-13

2. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2023-07-05

3. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10;eBioMedicine;2023-03

4. Application of enhanced computed tomography-based radiomics nomogram analysis to differentiate metastatic ovarian tumors from epithelial ovarian tumors;Journal of X-Ray Science and Technology;2022-11-24

5. Prognostic Value of Elevated Pre-treatment Serum CA-125 in Epithelial Ovarian Cancer: A Meta-Analysis;Frontiers in Oncology;2022-04-07